SCHEMBL448644

SCHEMBL448644

CC(c1nc2ccccc2c(=O)n1-c1ccccc1)N(C)S(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 12/20 0.50
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
ADAMTS4 O75173 1/20 0.44
PDE10A Q9Y233 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
PLA2G1B P04054 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451421 0.94 CXCR3 (0.50) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL448941 0.93 CXCR3 (0.50) CXCR3ALDH1A1HTTKDM4ELMNA
SCHEMBL450680 0.93 CXCR3 (0.49) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL453684 0.93 CXCR3 (0.59) CXCR3
SCHEMBL451676 0.93 CXCR3 (0.49) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL452894 0.91 CXCR3 (0.51) CXCR3PDE10AALDH1A1LMNAGAA
SCHEMBL451971 0.91 CXCR3 (0.47) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL454538 0.91 CXCR3 (0.47) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL448940 0.91 CXCR3 (0.45) CXCR3MEN1HSP90AA1MAPTKMT2A
SCHEMBL452939 0.90 HTR6 (0.51) CXCR3MEN1KMT2APDE10AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
EP-1521746-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2005-04-13 EP disclosed
WO-2003076418-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885MEN1 4424/4885HSP90AA1 1722/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885MEN1 4424/4885HSP90AA1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.